Abstract
COVID-19 booster vaccinations are essential for addressing waning immunity and the emergence of new variants. In sub-Saharan Africa, data on vaccine-induced immunity remains limited. This study examined functional antibody responses against various SARS-CoV-2 variants before and after booster vaccinations in Ghanaian adults between November 2022 and February 2023. While natural exposure (measured by N antigen antibodies) was widespread across both vaccinated and unvaccinated groups, RBD-specific IgG levels were significantly higher in vaccinated individuals, except for the Omicron variant. Booster effectiveness varied by platform: Pfizer-BioNTech elicited broad responses across all variants, whereas the J&J booster showed limited gains against Delta and Omicron. Extended intervals between doses may have enhanced antibody quality through affinity maturation, though Omicron continues to demonstrate significant immune evasion.
Introduction
The global effort to combat COVID-19 relies heavily on booster vaccinations to maintain protection against evolving variants. However, there is a significant data gap regarding vaccine performance in sub-Saharan Africa (SSA), where unique environmental factors and high natural exposure rates may influence immune responses. This study addresses this gap by evaluating the functional activity of vaccine-induced antibodies in a cohort of adults in Ghana, comparing different vaccine platforms against a backdrop of high community transmission.
Methods
Researchers conducted a longitudinal study of 122 adults (86 vaccinated, 36 unvaccinated) in Ghana. Immune responses were assessed using three primary methods:
- Indirect ELISA: Quantified IgG antibodies against the Nucleocapsid (N) protein and the Spike Receptor Binding Domain (RBD) of five variants (Wild-type, Alpha, Beta, Delta, and Omicron).
- ACE-2 Inhibition Assay: Measured the ability of plasma antibodies to block the interaction between the viral spike protein and human ACE-2 receptors.
- Plaque Reduction Neutralization Test (PRNT80): Used live SARS-CoV-2 virus to determine the actual neutralizing capacity of the participants' plasma.
Results
Analysis of N-antigen-specific antibodies revealed that natural exposure was nearly universal, with similar levels found in both vaccinated and unvaccinated individuals. In contrast, RBD-specific IgG levels were significantly higher in vaccinated participants than in those with only natural exposure for most variants, though this difference was less pronounced for Omicron.
The study highlighted a clear divergence in booster performance between vaccine types. The Pfizer-BioNTech (mRNA) booster significantly increased RBD IgG levels against all tested variants. Conversely, the Johnson & Johnson (adenoviral) booster failed to significantly increase defenses against the Delta and Omicron variants. While live virus neutralization against the Wild-type virus improved significantly after boosting, neutralization of Omicron remained stable, indicating persistent evasion by this variant.
Discussion and Conclusion
A notable finding was the potential benefit of the extended intervals between vaccine doses observed in this cohort (averaging over 450 days). Such delays may allow for better affinity maturation of B-cells, resulting in higher-quality antibodies. However, the muted response to Omicron remains a concern, suggesting that current boosters may have reached a ceiling of effectiveness against highly mutated variants.
Limitations of the study include a relatively small and young sample size. Future research should investigate long-term immunity durability and the impact of regional co-infections, such as malaria, on vaccine-induced responses in African populations. These findings are crucial for tailoring public health policies and booster strategies in resource-limited settings.
Summary updated